Gland Pharma

Hyderabad, India Founded: 1978 • Age: 48 yrs Listed Acquired By Fosun Fortune India 500 · #414 Fortune MNC 500 · #135
Generic injectable drugs are manufactured across therapeutic segments.

About Gland Pharma

Gland Pharma is a publicly listed company based in Hyderabad (India) founded in 1978 by Ravi Penmetsa and Pvn Raju, and was acquired by Fosun in July 2016. Generic injectable drugs are manufactured across therapeutic segments. The company has 4,332 employees. Gland Pharma has completed 1 acquisition, including Cenexi. Gland Pharma was last valued at $445.93 million in November 2013. Its chief executive, as recorded, is Srinivas Sadu. Its Indian entity Gland Pharma Ltd reported revenue of β‚Ή6,747 Cr. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and Formulation.

Company details

The company was founded in 1978 in Hyderabad, India, and operates in the pharmaceutical sector as a manufacturer of generic injectable drugs. A portfolio of products has been established in sterile injectables, oncology, and ophthalmics, with emphasis on complex injectables and various delivery systems. Diverse injectable needs are addressed through a stable supply chain, serving global markets from its base in India.

Gland Pharma is ranked #414 on the Fortune India 500 (2025) and #135 on the Fortune MNC 500 India (2026).

Recognitions & Rankings of Gland Pharma

Fortune India 500 2025 edition
Rank#414
Total income
₹5,727 Cr
Profit
₹699 Cr
Last year #382
Fortune MNC 500 India 2026 edition
Rank#135
Total income
₹5,727 Cr
Profit
₹699 Cr
Last year #124
  • Headquarters Hyderabad, India
  • Employees 4,332
  • Founders Ravi Penmetsa, Pvn Raju
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website glandpharma.com
  • Social LinkedIn X Facebook Instagram YouTube
  • Acquired by Fosun (Jul 2016)
  • Legal Name Gland Pharma Ltd.
Key Metrics
  • Market Cap
    ₹55,871 Cr

    GLAND · NSE

  • Share Price
    ₹3,348.00

    -1.12% today

  • Revenue
    ₹6,431 Cr

    FY 2025-26 · +14.5% YoY

  • EBITDA
    ₹1,605 Cr

    Margin 25.0%

  • Net Profit
    ₹1,042 Cr

    FY 2025-26 · +49.5% YoY

  • P/E (TTM)
    43.9x

    P/B 5.2x

  • ROE
    10.5%

    ROCE 14.6%

  • Debt / Equity
    0.03

    Interest cover 2.8x

  • Latest Funding Round
    $208.59M (USD), Unspecified

    Nov 2013

  • Investors
    KKR

    & 2 more

  • Employee Count
    4,332
  • Investments & Acquisitions
  • Acquired by
    Fosun

    (Jul 2016)

Apps and channels of Gland Pharma

its YouTube channel Gland Pharma has 184 subscribers and 7 videos.

Gland Pharma
YouTube 184 subscribers 7 videos Science & Technology
Open channel

Videos from Gland Pharma

The most watched videos on Gland Pharma's YouTube channel, Gland Pharma (184 subscribers). Click a video to play it here.

Gland Pharma Corporate Video 2021
6.5K views
Gland Pharma | Corporate Video
1.3K views
43rd Annual General Meeting | Gland Pharma Limited
1K views
Rural Development Initiatives by Gland Pharma Limited | CSR Initiatives
842 views

More on Gland Pharma.

Funding Insights of Gland Pharma

  • Total Rounds 1
  • Last Round Unspecified β€” $208.59M
  • First Round $208.59M

    (Nov 2013)

  • Investors Count 2

All 1 funding rounds of Gland Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Nov 2013$208.59MUnspecified$445.93MKKR
Valuation history
DateValuationStage
Nov 2013$445.93Mβ€’β€’β€’β€’β€’β€’β€’β€’

Last known valuation $445.93M (Nov 2013). 3 investors in total: 3 institutional.

Investors in Gland Pharma

Gland Pharma has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include KKR, Fosun and Gland Celsus Bio Chemicals.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Multiple sectors are invested in by this private equity firm.
1976kkr.comNew York, United States
Provider of legal, accounting, book keeping, and tax consulting services
2007glandcelsus.comHyderabad, India
Diversified investment, asset management, and insurance services are offered globally.
1992fosun.comShanghai, China
Premium access

Investor details for Gland Pharma

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Gland Pharma Ltd (Gland Pharma)

Gland Pharma Ltd is the primary company behind Gland Pharma. The board of Gland Pharma Ltd currently have 8 directors; the longest-serving is Udo Jahannes Vetter, appointed in 2018. 27 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Udo Jahannes Vetter
DIN 00707474
Director07 Feb 20188 yrs 9 moGland Pharma Ltd
Srinivas Sadu
DIN 06900659
Whole-time director25 Apr 20197 yrs 6 moGland Pharma Ltd
Essaji Goolam Vahanvati
DIN 00157299
Director30 Sep 20206 yrs 1 moGland Pharma Ltd
Jia Ai Zhang
DIN 09170927
Director17 May 20215 yrs 6 moGland Pharma Ltd
Naina Lal Kidwai
DIN 00017806
Director17 May 20215 yrs 6 moGland Pharma Ltd
Wei Huang
DIN 10818586
Director04 Nov 20242 yrsGland Pharma Ltd
William Robert Keller
DIN 11593622
Director15 Jun 20265 moGland Pharma Ltd
Xingli Wang
DIN 11899926
Additional Director01 Oct 20261 moGland Pharma Ltd

People of Gland Pharma

5 people are tracked at Gland Pharma (4 in leadership, 1 in team); the tracked headcount is 4,332.

NameRoleGroup
Ravi Penmetsa
Co-FounderLeadership
Pvn Raju
Co-FounderLeadership
CEO & Managing DirectorLeadership
Shyamakant Giri
CEOLeadership
Raghava Bomminayuni
Senior ExecutiveTeam
Premium access

Complete people profiles for Gland Pharma

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Gland Pharma

Gland Pharma is a publicly listed company on the NSE with ticker symbol GLAND in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date20 Nov 2020
  • Listed onBSE: 543245 · NSE: GLAND
  • Listed entityGland Pharma Ltd.
  • Exchange sectorHealth technology
  • ISININE068V01023
  • Share price₹3,052.30 (-1.26% on the day) · 2026-10-14
  • Market capitalisation₹50,959 Cr
  • Price to earnings44.6
  • EPS (diluted, trailing year)₹68.47
  • Dividend yield0.65%
  • Volume (last session)178,927

Financials of Gland Pharma

Exchange-reported figures of Gland Pharma Ltd, the listed company behind Gland Pharma (NSE: GLAND).

Financial Highlights

FY 2025-26 Β· Consolidated
Revenue
₹6,431 Cr
+14.5% YoY
EBITDA
₹1,605 Cr
+26.5% YoY
Profit After Tax
₹1,042 Cr
+49.5% YoY
Net Worth
₹10,358 Cr
+13.2% YoY
Total Assets
₹10,878 Cr
+12.7% YoY
Total Debt
₹284 Cr
-9.6% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue6,4315,6165,6653,6254,4013,4632,633
Revenue growth+14.5%-0.9%+56.3%-17.6%+27.1%+31.5%-
EBITDA1,6051,2691,3339681,5101,302955
EBITDA margin+25.0%+22.6%+23.5%+26.7%+34.3%+37.6%+36.3%
Profit before tax1,4651,0631,1331,0551,6191,335993
Net profit1,0426977728211,208997760
Net profit margin+16.2%+12.4%+13.6%+22.6%+27.5%+28.8%+28.9%
EPS (β‚Ή)62.3542.4046.9047.4273.7560.9449.88
Balance sheet
Total assets10,8789,6529,2747,9657,1645,9103,654
Net worth10,3589,1518,7247,9597,1585,9033,646
Total debt2843143724.454.745.004.96
Cash & bank3,3592,5561,8393,7713,0933,0061,325
Net working capital6,1095,4254,4786,1725,1154,6112,488
Cash flow
Cash from operations1,031915997364791605701
Cash from investing1881,718(1,749)1,211(999)(1,520)(761)
Cash from financing(417)(433)(799)14.9234.901,238(6.87)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue1,8341,8001,7431,6951,4871,5061,4251,384
Revenue growth (YoY)+23.3%+19.6%+22.3%+22.5%+5.8%+7.4%--
Other income69.0561.2311163.1784.1657.5344.0358.49
EBITDA484489513411314368348360
EBITDA margin+26.4%+27.2%+29.4%+24.2%+21.1%+24.4%+24.4%+26.0%
Depreciation11511110910810610195.7696.33
Interest7.144.3610.033.937.8211.507.4522.82
Profit before tax431435506362284313288299
Tax14011813910110097.2610294.61
Net profit291317367261184215187205
EPS (β‚Ή)17.6219.2222.2315.8711.1513.0811.3212.42
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue4,5524,1164,1673,6174,4013,4632,633
Revenue growth+10.6%-1.2%+15.2%-17.8%+27.1%+31.5%-
EBITDA1,6391,4431,4099621,5111,302955
EBITDA margin+36.0%+35.1%+33.8%+26.6%+34.3%+37.6%+36.3%
Profit before tax1,7481,4661,4051,0481,6191,335993
Net profit1,3151,0881,0448151,209997760
Net profit margin+28.9%+26.4%+25.0%+22.6%+27.5%+28.8%+28.9%
EPS (β‚Ή)78.8866.1463.3447.1173.7860.9549.88
Balance sheet
Total assets10,8609,7839,0207,9597,1655,9103,654
Net worth10,8109,7558,9957,9537,1585,9033,646
Total debt2.755.233.664.454.745.004.96
Cash & bank3,1782,4331,5993,7673,0863,0051,325
Net working capital5,7895,2454,1586,1595,1084,6112,488
Cash flow
Cash from operations1,1351,0741,136368791605701
Cash from investing(74.03)1,582(2,918)1,211(1,007)(1,521)(761)
Cash from financing(316)(340)(7.40)14.9234.901,238(6.87)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue1,4021,2871,2621,1781,0741,0391,0301,011
Revenue growth (YoY)+30.5%+23.9%+22.4%+16.5%+1.1%+2.7%--
Other income71.3858.8210660.2182.5954.7443.7265.06
Total expenses854813754780699680636620
EBITDA548474508397375359394391
EBITDA margin+39.1%+36.8%+40.2%+33.7%+34.9%+34.5%+38.3%+38.7%
Depreciation45.1543.9543.1144.5344.8443.7743.0743.77
Interest3.150.696.170.503.977.443.4518.31
Profit before tax571488565412409362391394
Tax14612314410510793.1210199.01

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 17 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue1,8341,8001,7431,6951,4871,5061,4251,384
Revenue growth (YoY)+23.3%+19.6%+22.3%+22.5%+5.8%+7.4%--
Other income69.0561.2311163.1784.1657.5344.0358.49
EBITDA484489513411314368348360
EBITDA margin+26.4%+27.2%+29.4%+24.2%+21.1%+24.4%+24.4%+26.0%
Depreciation11511110910810610195.7696.33
Interest7.144.3610.033.937.8211.507.4522.82
Profit before tax431435506362284313288299
Tax14011813910110097.2610294.61
Net profit291317367261184215187205
EPS (β‚Ή)17.6219.2222.2315.8711.1513.0811.3212.42
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue6,4315,6165,6653,6254,4013,4632,633
Revenue growth+14.5%-0.9%+56.3%-17.6%+27.1%+31.5%-
Other income316214170240224135139
Total expenses4,8254,3484,3322,6562,8912,1611,678
Employee cost1,6291,4021,257403339311278
EBITDA1,6051,2691,3339681,5101,302955
EBITDA margin+25.0%+22.6%+23.5%+26.7%+34.3%+37.6%+36.3%
Depreciation42437834514711098.7894.59
Interest33.2842.0026.207.455.243.417.18
Profit before tax1,4651,0631,1331,0551,6191,335993
Tax437364360274407338220
Net profit1,0426977728211,208997760
Net profit margin+16.2%+12.4%+13.6%+22.6%+27.5%+28.8%+28.9%
EPS (β‚Ή)62.3542.4046.9047.4273.7560.9449.88
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital16.4816.4816.4716.4716.4316.3615.50
Reserves & surplus10,3419,1348,7077,9427,1415,8873,631
Shareholders' funds (net worth)10,3589,1518,7247,9597,1585,9033,646
Minority interest0.000.000.000.000.000.000.00
Secured loans0.000.000.000.000.000.000.00
Unsecured loans2843143724.454.745.004.96
Total debt2843143724.454.745.004.96
Total liabilities10,8789,6529,2747,9657,1645,9103,654
Assets
Gross block6,7855,6135,0122,2952,0811,4311,348
Net block4,4924,1473,9471,5711,502954968
Capital work in progress342151238177191338188
Investments0.000.000.000.001550.000.00
Inventories1,7441,6851,6551,9451,1861,275756
Sundry debtors1,8911,5171,5598711,199671602
Cash & bank balances3,3592,5561,8393,7713,0933,0061,325
Loans & advances5321,025592313219172163
Total current assets7,5276,7835,6456,9015,6975,1242,846
Total current liabilities1,4181,3581,167728582512358
Net working capital6,1095,4254,4786,1725,1154,6112,488
Total assets10,8789,6529,2747,9657,1645,9103,654
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash2,5563571,909319492170236
Net cash from operating activities1,031915997364791605701
Net cash from investing activities1881,718(1,749)1,211(999)(1,520)(761)
Net cash from financing activities(417)(433)(799)14.9234.901,238(6.87)
Net change in cash8032,199(1,552)1,590(174)323(66.91)
Closing cash3,3592,5561,8393,7713,0933,0061,325
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+14.5%-0.9%+56.3%-17.6%+27.1%+31.5%-
EBITDA growth+26.5%-4.8%+37.7%-35.9%+16.0%+36.3%-
PBT growth+37.8%-6.2%+7.4%-34.8%+21.3%+34.4%+9997.0%
Net income growth+49.5%-9.7%-5.9%-32.1%+21.2%+31.2%-
Revenue CAGR (3Y)+21.1%+8.5%+17.8%+11.2%---
EBITDA CAGR (3Y)+18.4%-5.6%+0.8%+0.5%---
Profitability & leverage
Net income margin+16.0%+12.4%+13.6%+21.6%+27.5%+28.8%+29.4%
Return on capital employed+14.6%+11.7%+13.4%+14.0%+24.8%+28.0%+27.4%
Return on net worth+10.5%+7.8%+9.3%+10.3%+18.6%+20.9%+21.2%
Debt / equity0.030.040.020.000.000.000.00
Long-term debt / equity0.010.010.010.000.000.000.00
Interest cover2.824.712.650.910.370.280.83
Efficiency & per share
Fixed asset turnover1.041.061.551.662.512.491.95
Inventory turnover3.753.363.152.323.583.413.48
Debtors turnover3.773.654.663.724.715.444.38
EPS (β‚Ή)62.3542.4046.9047.4273.7560.9449.88
Dividend per share (β‚Ή)20.0018.0020.000.000.000.000.00
Book value per share (β‚Ή)628.67555.40529.65483.23435.64360.86235.32
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue1,4021,2871,2621,1781,0741,0391,0301,011
Revenue growth (YoY)+30.5%+23.9%+22.4%+16.5%+1.1%+2.7%--
Other income71.3858.8210660.2182.5954.7443.7265.06
Total expenses854813754780699680636620
EBITDA548474508397375359394391
EBITDA margin+39.1%+36.8%+40.2%+33.7%+34.9%+34.5%+38.3%+38.7%
Depreciation45.1543.9543.1144.5344.8443.7743.0743.77
Interest3.150.696.170.503.977.443.4518.31
Profit before tax571488565412409362391394
Tax14612314410510793.1210199.01
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue4,5524,1164,1673,6174,4013,4632,633
Revenue growth+10.6%-1.2%+15.2%-17.8%+27.1%+31.5%-
Other income304215167240224135139
Total expenses2,9132,6742,7592,6542,8902,1611,678
Employee cost529439410400339311278
EBITDA1,6391,4431,4099621,5111,302955
EBITDA margin+36.0%+35.1%+33.8%+26.6%+34.3%+37.6%+36.3%
Depreciation17616916214711098.7894.59
Interest18.0722.847.847.415.243.417.18
Profit before tax1,7481,4661,4051,0481,6191,335993
Tax449376362273407338220
Net profit1,3151,0881,0448151,209997760
Net profit margin+28.9%+26.4%+25.0%+22.6%+27.5%+28.8%+28.9%
EPS (β‚Ή)78.8866.1463.3447.1173.7860.9549.88
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital16.4816.4816.4716.4716.4316.3615.50
Reserves & surplus10,7949,7398,9797,9377,1425,8873,631
Shareholders' funds (net worth)10,8109,7558,9957,9537,1585,9033,646
Secured loans0.000.000.000.000.000.000.00
Unsecured loans2.755.233.664.454.745.004.96
Total debt2.755.233.664.454.745.004.96
Total liabilities10,8609,7839,0207,9597,1655,9103,654
Assets
Gross block2,9152,7982,5802,2952,0811,4311,348
Net block1,6881,7451,6941,5711,502954968
Capital work in progress13842.21120177191338188
Investments3,2932,7902,3868.161630.550.00
Inventories1,2651,2541,2601,9451,1861,275756
Sundry debtors1,5211,1431,1718631,075671602
Cash & bank balances3,1782,4331,5993,7673,0863,0051,325
Loans & advances459937541313343172163
Total current assets6,4225,7674,5716,8885,6905,1232,846
Total current liabilities633522413729582512358
Net working capital5,7895,2454,1586,1595,1084,6112,488
Total assets10,8609,7839,0207,9597,1655,9103,654
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash2,4331161,905311492170236
Net cash from operating activities1,1351,0741,136368791605701
Net cash from investing activities(74.03)1,582(2,918)1,211(1,007)(1,521)(761)
Net cash from financing activities(316)(340)(7.40)14.9234.901,238(6.87)
Net change in cash7452,316(1,789)1,594(181)322(66.91)
Closing cash3,1782,4331,5993,7673,0863,0051,325
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+10.6%-1.2%+15.2%-17.8%+27.1%+31.5%-
EBITDA growth+13.6%+2.4%+46.4%-36.3%+16.0%+36.3%-
PBT growth+19.3%+4.3%+34.1%-35.3%+21.3%+34.5%+44.7%
Net income growth+20.9%+4.3%+28.0%-32.6%+21.3%+31.2%-
Revenue CAGR (3Y)+8.0%-2.2%+6.4%+11.2%+29.1%+28.8%+21.2%
EBITDA CAGR (3Y)+19.4%-1.5%+2.7%+0.2%+30.1%+34.5%+15.2%
Profitability & leverage
Net income margin+28.6%+26.5%+25.0%+21.5%+27.5%+28.8%+29.4%
Return on capital employed+17.1%+15.8%+16.7%+14.0%+24.9%+28.0%+30.6%
Return on net worth+12.6%+11.6%+12.3%+10.3%+18.6%+20.9%+23.8%
Debt / equity0.000.000.000.000.000.000.00
Long-term debt / equity0.000.000.000.000.000.000.00
Interest cover1.241.790.630.910.370.280.83
Efficiency & per share
Fixed asset turnover1.591.531.711.652.512.492.05
Inventory turnover3.613.272.602.313.583.413.16
Debtors turnover3.423.564.103.735.045.444.75
EPS (β‚Ή)78.8866.1463.3447.1173.7860.9549.88
Dividend per share (β‚Ή)20.0018.0020.000.000.000.000.00
Book value per share (β‚Ή)656.11592.08546.13482.90435.68360.86235.32

Investments & Acquisitions by Gland Pharma

Gland Pharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Cenexi.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Pre-formulation and formulation services are provided in pharmaceuticals.
cenexi.com2004Nov 2022β€’β€’β€’β€’
Premium access

Complete acquisition details for Gland Pharma

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Gland Pharma

6 dated milestones of Gland Pharma across 44 years, from founding to its latest funding, stage changes and deals.

  1. Founded Gland Pharma is founded.
  2. Funding First funding round of $208.6M.
  3. Milestone Reaches Minicorn status.
  4. Exit Acquired by Fosun.
  5. IPO Lists on the stock exchange (IPO).
  6. Acquisition Acquires Cenexi.

Web traffic of Gland Pharma

The website of Gland Pharma (glandpharma.com) receives about 8.4K visits a month and ranks #3,685,423 among all websites worldwide, #4,728 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    8.4K

    ▲ 56.1% vs previous month

  • Unique visitors
    2.4K

    per month

  • Global rank
    #3,685,423

    among all websites

  • Category rank
    #4,728

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Gland Pharma. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
cadilapharma.com
100%
18.5K#1,452,788View details
greencrossindia.com
62%
1.7K#3,821,526View details
genixpharma.com
62%
View details
cipla.com
38%
200.9K#203,362View details

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as Gland Pharma (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Developer of integrated contract research development and manufacturing services
2007Bengaluru, Karnataka, IndiaUSD 35.74 MUSD 226.38 M2,062
Pharmaceutical and biotechnology company
2005Hyderabad, Telangana, IndiaUSD 229.73 MUSD 726.15 M548
India's leading healthcare products distribution platform
2018Mumbai, Maharashtra, IndiaUSD 59.67 MUSD 702.49 M557
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Gland Pharma

Gland Pharma: Expects Steady US Revenue Growth From New Products And CDMO Business With No Expected Fluctuations; The Company Maintains Full-Year Growth Guidance Of 15% On A Constant Currency Basis, Anticipating Better Performance In The Rest Of The World Market.
Exchange Update β€’ 8 days ago
Gland Pharma: Names Mr. Xiao Le As Chief Investment Officer For Gland Pharma International Pte. Ltd. Starting November 09, 2026; He Has Over 15 Years Of Experience In Investment And Asset Management.
Exchange Update β€’ 8 days ago
GLAND: Q2 REVENUE 18.34B RUPEES VS 14.87B (YOY)
Exchange Update β€’ 11 days ago
GLAND: Q2 CONS NET PROFIT 2.91B RUPEES VS 1.84B (YOY)
Exchange Update β€’ 11 days ago
GLAND: Q2 EBITDA 4.84B RUPEES VS 3.14B (YOY); Q2 EBITDA MARGIN 26.40% VS 21.11% (YOY)
Exchange Update β€’ 11 days ago
Gland Pharma: Gets USFDA Green Light For Methylprednisolone Acetate Injectable Suspension; Approval Covers Single-Dose And Multiple-Dose Vials; Product Expected Sales In The US Are About USD 214 Million.
Exchange Update β€’ 14 days ago
GLAND: Rs. 28.31 Crores BSE Block Trade; for ~ 100,031 Shares, at Rs. 2830.35
Exchange Update β€’ 22 days ago
GLAND: Rs. 37.23 Crores BSE Block Trade; for ~ 122,556 Shares, at Rs. 3038.00
Exchange Update β€’ 29 days ago
GLAND: Rs. 18.16 Crores BSE Block Trade; for ~ 59,769 Shares, at Rs. 3038.00
Exchange Update β€’ 29 days ago
GLAND: RS. 71.91 CRORES BSE BLOCK TRADE; FOR ~ 235,000 SHARES, AT RS. 3060.00
Exchange Update β€’ 1 month ago
Premium access

Complete news archive for Gland Pharma

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Gland Pharma

Gland Pharma was founded in 1978 and raised its 1st funding round 35 years after it was founded.

Gland Pharma is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.

Srinivas Sadu is the CEO of Gland Pharma, as recorded in our data.

Gland Pharma has 4,332 employees.

The primary company behind Gland Pharma, Gland Pharma Ltd, reported revenue of β‚Ή6,747 Cr for FY 2026, up 14% year on year.

The company was founded in 1978 in Hyderabad, India, and operates in the pharmaceutical sector as a manufacturer of generic injectable drugs. A portfolio of products has been established in sterile injectables, oncology, and ophthalmics, with emphasis on complex injectables and various delivery systems. Diverse injectable needs are addressed through a stable supply chain, serving global markets from its base in India.

Yes, Gland Pharma is publicly traded on NSE under the ticker symbol GLAND.

Gland Pharma has made 1 acquisition, including Cenexi.

Gland Pharma has 3 investors. Key investors include KKR, Fosun, and Gland Celsus Bio Chemicals.

The valuation of Gland Pharma is $445.93M as of Nov 2013.

Gland Pharma operates through Gland Pharma Ltd.

Yes. Gland Pharma was acquired by Fosun in July 2016.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available